Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles EMBO Molecular Medicine Year : 2016

Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success

Abstract

Comment on CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. [EMBO Mol Med. 2016]
Fichier principal
Vignette du fichier
EMMM-8-439.pdf (148.35 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02150381 , version 1 (07-06-2019)

Identifiers

Cite

Tuan Huy Nguyen, Ignacio Anegon. Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success. EMBO Molecular Medicine, 2016, 8 (5), pp.439-441. ⟨10.15252/emmm.201606325⟩. ⟨inserm-02150381⟩
24 View
82 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More